Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Fate Therapeutics initiates phase 1 trial for solid tumour treatment

January 9, 2024 Research and Development Fate Therapeutics, Oncology, solid tumours

Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …
News

Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery

January 4, 2024 Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology

Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …
News

AstraZeneca and Sanofi’s Beyfortus approved in China

January 2, 2024 Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi

AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …
News

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

January 2, 2024 Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …
News

Ocelot Bio gains FDA ODD for OCE-205 for ascites treatment

December 21, 2023 Research and Development Gastrointestinal tract, Ocelot Bio, ascites

Ocelot Bio has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to OCE-205 …
News

Tracon Pharmaceuticals shares update on ENVASARC phase 2 trial

December 21, 2023 Research and Development ENVASARC, Pharmacy, Tracon Pharmaceuticals, clinical trial

Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 …
News

Gilead and Compugen enter exclusive license agreement for immunotherapy programme

December 20, 2023 Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology

Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …
News
markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

December 20, 2023 Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …
News

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023 Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
News

GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment

December 18, 2023 Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
News

InnoCare shares results from phase 2 trial for atopic dermatitis treatment

December 18, 2023 Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial

InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …
News

First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617

December 15, 2023 Research and Development Cullinan Oncology, Oncology, clinical trial, tumours

Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …
News

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023 Research and Development AI, Acceleration Consortium, Merck, Pharmacy, experimentation

Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on …
News

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023 Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership

ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …
News

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023 Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity

Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026